Amgen Joins AI Cardiology Surge as Market Grows from $2.78B to $14B by 2034
AMGN•The global AI cardiology market, valued at $2.78 billion, is projected to exceed $14 billion by 2034 as hospitals deploy machine learning to reduce diagnostic backlogs. Amgen is cited among five players driving this expansion alongside device segments forecast to grow from $31.12 billion to $42.39 billion by 2031.
1. AI Cardiology Market Outlook
Global AI cardiology market worth $2.78 billion is forecast to reach $14 billion by 2034 as hospitals adopt machine learning tools to tackle growing diagnostic backlogs, with U.S. heart disease costs approaching $5 trillion annually per American Heart Association estimates.
2. Interventional Devices and Wearables Growth
Interventional cardiology devices market is projected to rise from $31.12 billion to $42.39 billion by 2031, driven by minimally invasive procedures and AI-powered imaging; wearable ECG monitoring stands at $5.9 billion and is expanding at a 23.4% annual rate.
3. Amgen’s Position in Diagnostics Convergence
Amgen is cited alongside VentriPoint Diagnostics, BridgeBio Pharma, Bristol Myers Squibb and Arrowhead Pharmaceuticals as one of five players at the center of this AI-driven cardiac diagnostics and device convergence, positioning it to benefit from sector growth.
